Jazz Pharmaceuticals to Participate in Upcoming Investor Events

Rhea-AI Summary

Jazz Pharmaceuticals (Nasdaq: JAZZ) will host investor webcasts in January 2026 to review clinical and corporate updates.

Key events: a zanidatamab HERIZON-GEA-01 Phase 3 results webcast on Jan 9, 2026 at 6:30 a.m. PT / 3:30 p.m. GMT following the oral presentation at ASCO GI on Jan 8, 2026; and a corporate presentation by CEO Renee Gala at the J.P. Morgan Healthcare Conference on Jan 13, 2026 at 11:15 a.m. PST / 7:15 p.m. GMT.

Audio webcasts and 30-day replays will be available via the Investors section of Jazz Pharmaceuticals' website.

DUBLIN, Dec. 17, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor events:

Zanidatamab HERIZON-GEA-01 Investor Webcast on Friday, January 9, 2026

• The Company will host an investor webcast on Friday, January 9, 2026, at 6:30 a.m. PT / 3:30 p.m. GMT to review results from the Phase 3 zanidatamab HERIZON-GEA-01 trial. The webcast will include commentary from the Company's senior management and Dr. Geoffrey Ku, Associate Attending physician on the Gastrointestinal Oncology Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center. The webcast will take place following the oral presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026.

44^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026

• The Company will webcast its corporate presentation at the 44^th Annual J.P. Morgan Healthcare Conference. Renee Gala, president and chief executive officer, will provide an overview of the company strategy and a business update on Tuesday, January 13, 2026, at 11:15 a.m. PST / 7:15 p.m. GMT.

Audio webcasts of the presentations may be accessed via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be available on the website for 30 days.  

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing potentially life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Contacts:

Investors:
Jack Spinks
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com     
Ireland, +353 1 634 3211
U.S., +1 650 496 2717

Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland, +353 1 637 2141
U.S., +1 215 867 4948

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-participate-in-upcoming-investor-events-302645145.html

SOURCE Jazz Pharmaceuticals plc

FAQ

When is Jazz Pharmaceuticals' zanidatamab HERIZON-GEA-01 Phase 3 results webcast for JAZZ?

The webcast is scheduled for Jan 9, 2026 at 6:30 a.m. PT / 3:30 p.m. GMT.

Will Jazz discuss the ASCO GI presentation for zanidatamab before the Jan 9, 2026 webcast?

Yes. The webcast follows the oral presentation at the ASCO Gastrointestinal Cancers Symposium on Jan 8, 2026.

When will Jazz Pharmaceuticals (JAZZ) present at the 44th Annual J.P. Morgan Healthcare Conference?

The company presentation is set for Jan 13, 2026 at 11:15 a.m. PST / 7:15 p.m. GMT, delivered by CEO Renee Gala.

How can investors access Jazz Pharmaceuticals' (JAZZ) January 2026 webcasts and replays?

Audio webcasts and a replay (available for 30 days) can be accessed via the Investors section at investor.jazzpharma.com.

Who will comment on the zanidatamab HERIZON-GEA-01 results during the JAZZ investor webcast?

Commentary will come from senior management and Dr. Geoffrey Ku, associate attending physician at Memorial Sloan Kettering Cancer Center.